Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma - Wikidata - awgldk - TriplyDB

Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma

Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma

http://www.wikidata.org/entity/Q33409555

about

How to Improve Therapeutic Ratio in Radiotherapy of HCC Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma Antitumor effect of fructose 1,6-bisphosphate and its mechanism in hepatocellular carcinoma cells.Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread Risk factors for patients with stage IVB hepatocellular carcinoma and extension into the heart: prognostic and therapeutic implications.High dose and compartmental target volume may improve patient outcome after radiotherapy for pelvic bone metastases from hepatocellular carcinoma.The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study.Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis.

P2860

Q26738862-33071CA1-01A9-45E8-9D54-D179974D141A Q28084869-DBA5CBAF-7598-4DA9-88DB-401FD9A3A26E Q35003020-36BE9DA0-674F-41B1-8876-78DB217502E1 Q35553137-DB6AB2C0-F0EF-45F9-9054-0B32D5A02E1A Q37606692-BAC95B89-E62C-4015-9A02-DA136834AFC8 Q42199538-773F3564-BF55-44A2-B651-6C8BC0BE5113 Q49567283-CC2C32E6-023C-4711-A9B9-22AA38334C6B Q54971801-29FBB5E5-B041-497F-A79F-98F48E5C1266

P2860

Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma

http://www.wikidata.org/entity/Q33409555

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Feasibility of sorafenib combi ...... anced hepatocellular carcinoma

@ast

Feasibility of sorafenib combi ...... anced hepatocellular carcinoma

@en

type

label

Feasibility of sorafenib combi ...... anced hepatocellular carcinoma

@ast

Feasibility of sorafenib combi ...... anced hepatocellular carcinoma

@en

prefLabel

Feasibility of sorafenib combi ...... anced hepatocellular carcinoma

@ast

Feasibility of sorafenib combi ...... anced hepatocellular carcinoma

@en

P1433

Q33409555-A12C634E-50EA-4CE2-872B-559C905FCA71

P1476

Q33409555-207248EB-57BB-4E30-A1BE-28D8CD914FB7

P2093

Q33409555-64C8F689-AABE-482D-9A9C-E6137B57EEA2

Q33409555-F8D4DF7E-B98B-41F4-B694-838B1A168B08

P2860

Q33409555-1374889A-121E-4F7B-9222-DAC652F8604B

Q33409555-1542B95F-205E-422C-AC96-A911C50C0958

Q33409555-1B8041E4-A4D1-446A-82D6-77057C7B6C67

Q33409555-2809BAEA-6C1B-414D-8E09-6258067C068C

Q33409555-3B1F129B-F151-45F4-8BA3-6554F31E20B6

Q33409555-5214653A-251A-439E-949A-9A9F2BCD89B3

Q33409555-55520C41-B1B4-4142-8B1B-5B0121FD8F1E

Q33409555-651451E5-CC20-47FD-8736-F4A5ED940C23

Q33409555-7C1FA11F-791E-4CA5-BC4B-C4404AEAC247

Q33409555-7DC9FB8C-041D-4FD9-97C3-935B2A5ACB45

P304

Q33409555-C828C87E-9842-467A-B9AC-84DC2B65678B

P31

Q33409555-185D2F3C-AB08-4FCB-8DA0-38074DBED52C

P356

Q33409555-74024E9F-E229-4128-9061-B7050F00FB6F

P433

Q33409555-96EAA70D-D26C-4E2F-9AE8-C97161B3E699

P478

Q33409555-44BE7404-D673-40A2-AC0A-58FEBD0FB8DA

P50

Q33409555-6516704C-73E1-440D-8A94-658E34726411

Q33409555-DEAAEAC9-EF83-4ED6-9D09-576C209B99D8

Q33409555-FA105DA5-FAA9-468D-982A-7B1E859D7448

P577

Q33409555-27AF5103-C98C-4E9F-A6FE-80E44346CCDA

P5875

Q33409555-0AE4B11D-1C8F-49E1-BBC3-32069C2EE015

P698

Q33409555-655B7EC1-C8CD-40FD-84A5-541F0D68B69B

P932

Q33409555-444E3ED1-D8FB-40B4-86D3-67CABE125C2A

P356

YMJ.2013.54.5.1178

P1433

Yonsei Medical Journal

P1476

Feasibility of sorafenib combi ...... anced hepatocellular carcinoma

@en

P2093

Jihye Cha

http://www.w3.org/2001/XMLSchema#string

Jinsil Seong

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Management of hepatocellular carcinoma

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study.

P304

1178-1185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3349/YMJ.2013.54.5.1178

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255690217

http://www.w3.org/2001/XMLSchema#string

P698

23918567

http://www.w3.org/2001/XMLSchema#string

P932

3743177

http://www.w3.org/2001/XMLSchema#string